ISRCTN17148628进行中（未招募）2 期
A phase 2b, randomised, single-blind, non-inferiority clinical study to evaluate the immunogenicity and tolerability of SPVX02, a tetanus and diphtheria booster vaccine, against Tetadif® comparator vaccine in healthy adults
Stablepharma Ltd0 个研究点目标入组 160 人开始时间: 2026年8月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prophylaxis
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Participant is 18-60 years of age at the time of screening with a BMI =34.9 kg/m²
- •Participant is able to provide informed consent indicating that they are willing to participate and that they understand the purpose of the study and the assessments they are required to undergo as part of their involvement in the study
- •Participant is considered to be in good health with no current conditions that may significantly impair participant safety or influence the study results, as determined by the Investigator
- •Participant does not have any medical condition that causes primary or secondary immunodeficiency
- •Participant has previously received primary and/or booster immunisation with diphtheria and tetanus vaccines, as confirmed by GP records. Alternatively, in the absence of complete vaccination records, the participant has detectable screening tetanus and diphtheria antibody titres of =0.01 IU/mL
- •Participants who were born female and are of child-bearing potential must be practicing an acceptable, effective method of contraception for the duration of the study. Acceptable methods for this study include:
- •Hormonal contraception (use of hormonal contraception should start at least 28 days before the first administration of the study IMP)
- •Intrauterine device (IUD)
- •Intrauterine hormone-releasing system (IUS)
- •Bilateral tubal occlusion/ligation
- •Male or female condom with or without spermicide
- •Cap, diaphragm or sponge with a vaginal spermicide
- •Vasectomised partner (the vasectomised partner should be the sole partner for that volunteer and have received a medical assessment of surgical success)
- •Sexual abstinence (sexual abstinence is considered an effective method only if defined as refraining from heterosexual intercourse from signing the icf until the end of the study)
- •Participants who were born female and are not of child-bearing potential must be:
- •Postmenopausal: amenorrhea (no menstrual periods) for at least 12 months without an alternative medical cause
- •Permanently sterile: permanent sterilization methods include hysterectomy (removal of the womb), bilateral salpingectomy (surgical removal of the fallopian tubes), and bilateral oophorectomy (surgical removal of both ovaries).
- •Male participants must be willing to use a contraception method upon enrolment, during the course of the study, and for 1-month post-dose
排除标准
- •Serious and uncontrolled chronic disease (i.e., cardiac, pulmonary, renal, neurologic, metabolic, rheumatologic, etc.)
- •Known or suspected autoimmune disease or impairment of immunological function of any cause. Immune-mediated conditions that are stable and well-controlled (e.g.. Hashimoto thyroiditis) as well as those that do not require systemic immunosuppressants (e.g.. asthma, psoriasis, or vitiligo) may be permitted at the discretion of the Investigator and following discussion with the Medical Monitor. In participants with stable, treated hypothyroidism, mildly abnormal thyroid function tests may not be clinically significant and may be accepted at the discretion of the Investigator
- •Acute medical illness, with or without fever, or an oral or tympanic temperature >38°C within the 72 hours prior to dosing
- •Administration of immunoglobulin or other blood products within the last three months prior to screening; administration of corticosteroids (injected or oral) or other immunomodulatory therapy within 42 days prior to Day 1
- •A positive test result at screening for HIV, hepatitis C virus or hepatitis B virus. HIV-positive participants on antiretroviral therapy with CD4 count =500 cells/mm3 and HIV RNA =500 copies/mL within the past 365 days, are permitted at the discretion of the Investigator. Hepatitis C or Hepatitis B infection, if well controlled on stable therapy, with normal liver function and no evidence of immunosuppression, may be permitted at the discretion of the Investigator and following discussion with the Medical Monitor
- •History of allergic disease or any suspected or known hypersensitivity to any of the SPVX02 or Tetadif components
- •Any history of anaphylaxis in reaction to a vaccination
- •Unable to attend scheduled visits or unable to comply with the study procedures
- •Enrolled in another interventional clinical study or has received an investigational intervention in the last 6 months, or within 5 half-lives, whichever is longer
- •Any condition that would pose a health risk to the participant or interfere with the evaluation of either vaccine in the opinion of the Investigator
- •Female and of childbearing potential who does not agree either to remain abstinent or to use effective birth control during the period of the study
- •Intending to become pregnant or breast feeding during the period of the study
- •A history of Guillain-Barré syndrome
- •Receipt of a tetanus or diphtheria vaccination within the 10 years prior to enrolment, as determined from medical review of GP records
- •A previous history of diphtheria or tetanus disease within the last 25 years
- •History of Arthus-type hypersensitivity reaction
- •History of alcohol or substance abuse within the last 5 years. Participants with a positive DOA result at screening may be included at the discretion of the Investigator only if the result is attributable to prescribed or over-the-counter medication or other legitimate use, and there is no evidence of substance abuse or dependency. All decisions must be justified and documented
- •Unable to fulfil all the requirements of the study in the opinion of the Investigator
- •Significant psychiatric history in the last 2 years
- •Presence of permanent body art on both right and left upper arms that would obstruct the ability to observe local reactions at the injection site
- •Any other finding that, in the opinion of the Investigator or Sponsor, deems the subject unsuitable for the
研究者
相似试验
招募中
不适用
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (LAURITE 2)Moderate to Severe Glabellar LinesjRCT2031250845138
招募中
1 期
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT2024-519010-31-00Fondazione Melanoma Onlus80
招募中
不适用
Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with or without heparin. (EQUILIBRIX-S)jRCT2071260038800
进行中（未招募）
不适用
A trial examining the feasibility, acceptability and efficacy of a psychologist-supported digital program for anxiety and risky drinking in mothersRisky drinkingMental Health - AddictionMental Health - AnxietyMental Health - DepressionAnxietyDepressionACTRN12626000834358The University of Sydney130
已完成
1 期
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.Obesity2023-507758-34-00Rose Pharma Inc.12